Literature DB >> 20880358

Alterations of CXCR4 function in μ-opioid receptor-deficient glia.

Silvia Burbassi1, Rajarshi Sengupta, Olimpia Meucci.   

Abstract

The chemokine receptor CXCR4 and the μ-opioid receptor (MOR) are G-protein-coupled receptors that are essential for normal function of the nervous and immune systems. Several studies have suggested that MOR is a key regulator of CXCR4 in the brain; however, the molecular basis of the opioid-chemokine interaction is not fully understood, and it may involve different mechanisms in neuronal and glial cells. Our previous studies demonstrated that MOR stimulation specifically upregulates the protein ferritin heavy chain - an inhibitor of CXCR4 - in neurons, and suggested that additional mechanisms could be operative in glia. In this study, we investigated CXCR4 function in brains and astroglial cultures deprived of MOR. Reduced coupling of CXCR4 to G-proteins was found in brain slices and tissue homogenates of MOR(-/-) mice as compared with wild-type controls. CXCR4-induced signaling was also reduced in glial cultures from MOR(-/-) mice, as shown by analysis of CXCR4 downstream targets (Akt and ERK1/2). Pharmacological studies with δ-opioid receptor (DOR)-specific ligands suggested that DOR-CXCR4 interactions are implicated in the inhibition of CXCR4 in MOR-deficient cells both in vitro and in vivo. Moreover, increased CXCR4/DOR co-immunoprecipitation was found in brain tissue and cultured glia from MOR(-/-) mice. Importantly, CXCR4 function was restored by pretreatment with a DOR antagonist. Overall, these findings indicate that DOR plays a crucial role in the regulation of CXCR4 in glia, probably via silent receptor heterodimers. The data also suggest that the opiate system interferes with normal CXCR4 function in different ways, depending on receptor subtypes.
© 2010 The Authors. European Journal of Neuroscience © 2010 Federation of European Neuroscience Societies and Blackwell Publishing Ltd.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20880358      PMCID: PMC2956872          DOI: 10.1111/j.1460-9568.2010.07402.x

Source DB:  PubMed          Journal:  Eur J Neurosci        ISSN: 0953-816X            Impact factor:   3.386


  48 in total

Review 1.  Heterodimerization of G-protein-coupled receptors: pharmacology, signaling and trafficking.

Authors:  L A Devi
Journal:  Trends Pharmacol Sci       Date:  2001-10       Impact factor: 14.819

2.  Assessment of SNC 80 and naltrindole within a conditioned taste aversion design.

Authors:  A C Hutchinson; G R Simpson; J F Randall; X Zhang; S N Calderon; K C Rice; A L Riley
Journal:  Pharmacol Biochem Behav       Date:  2000-08       Impact factor: 3.533

Review 3.  Interactions between opioid and chemokine receptors: heterologous desensitization.

Authors:  Amber D Steele; Imre Szabo; Filip Bednar; Thomas J Rogers
Journal:  Cytokine Growth Factor Rev       Date:  2002-06       Impact factor: 7.638

Review 4.  Bidirectional heterologous desensitization of opioid and chemokine receptors.

Authors:  T J Rogers; A D Steele; O M Howard; J J Oppenheim
Journal:  Ann N Y Acad Sci       Date:  2000       Impact factor: 5.691

5.  Prolonged morphine treatment targets delta opioid receptors to neuronal plasma membranes and enhances delta-mediated antinociception.

Authors:  C M Cahill; A Morinville; M C Lee; J P Vincent; B Collier; A Beaudet
Journal:  J Neurosci       Date:  2001-10-01       Impact factor: 6.167

Review 6.  HIV and drug misuse in the Edinburgh cohort.

Authors:  Jeanne E Bell; J Carlos Arango; Roy Robertson; Ray P Brettle; Clifford Leen; Peter Simmonds
Journal:  J Acquir Immune Defic Syndr       Date:  2002-10-01       Impact factor: 3.731

Review 7.  Role of the alpha-chemokine stromal cell-derived factor (SDF-1) in the developing and mature central nervous system.

Authors:  Françoise Lazarini; To Nam Tham; Philippe Casanova; Fernando Arenzana-Seisdedos; Monique Dubois-Dalcq
Journal:  Glia       Date:  2003-04-15       Impact factor: 7.452

8.  Oligomerization of opioid receptors with beta 2-adrenergic receptors: a role in trafficking and mitogen-activated protein kinase activation.

Authors:  B A Jordan; N Trapaidze; I Gomes; R Nivarthi; L A Devi
Journal:  Proc Natl Acad Sci U S A       Date:  2001-01-02       Impact factor: 11.205

9.  CXCR4-activated astrocyte glutamate release via TNFalpha: amplification by microglia triggers neurotoxicity.

Authors:  P Bezzi; M Domercq; L Brambilla; R Galli; D Schols; E De Clercq; A Vescovi; G Bagetta; G Kollias; J Meldolesi; A Volterra
Journal:  Nat Neurosci       Date:  2001-07       Impact factor: 24.884

10.  CXCL12 inhibits expression of the NMDA receptor's NR2B subunit through a histone deacetylase-dependent pathway contributing to neuronal survival.

Authors:  J Nicolai; S Burbassi; J Rubin; O Meucci
Journal:  Cell Death Dis       Date:  2010-04-01       Impact factor: 8.469

View more
  14 in total

Review 1.  CXCL12 signaling in the development of the nervous system.

Authors:  Divakar S Mithal; Ghazal Banisadr; Richard J Miller
Journal:  J Neuroimmune Pharmacol       Date:  2012-01-21       Impact factor: 4.147

Review 2.  Toll-like receptors in chronic pain.

Authors:  Lauren Nicotra; Lisa C Loram; Linda R Watkins; Mark R Hutchinson
Journal:  Exp Neurol       Date:  2011-10-06       Impact factor: 5.330

Review 3.  Exploring the neuroimmunopharmacology of opioids: an integrative review of mechanisms of central immune signaling and their implications for opioid analgesia.

Authors:  Mark R Hutchinson; Yehuda Shavit; Peter M Grace; Kenner C Rice; Steven F Maier; Linda R Watkins
Journal:  Pharmacol Rev       Date:  2011-07-13       Impact factor: 25.468

4.  Neuronal ferritin heavy chain and drug abuse affect HIV-associated cognitive dysfunction.

Authors:  Jonathan Pitcher; Anna Abt; Jaclyn Myers; Rachel Han; Melissa Snyder; Alessandro Graziano; Lindsay Festa; Michele Kutzler; Fernando Garcia; Wen-Jun Gao; Tracy Fischer-Smith; Jay Rappaport; Olimpia Meucci
Journal:  J Clin Invest       Date:  2014-01-09       Impact factor: 14.808

Review 5.  In vivo opioid receptor heteromerization: where do we stand?

Authors:  D Massotte
Journal:  Br J Pharmacol       Date:  2014-07-01       Impact factor: 8.739

6.  Morphine potentiates neurodegenerative effects of HIV-1 Tat through actions at μ-opioid receptor-expressing glia.

Authors:  Shiping Zou; Sylvia Fitting; Yun-Kyung Hahn; Sandra P Welch; Nazira El-Hage; Kurt F Hauser; Pamela E Knapp
Journal:  Brain       Date:  2011-11-18       Impact factor: 13.501

7.  Interactive HIV-1 Tat and morphine-induced synaptodendritic injury is triggered through focal disruptions in Na⁺ influx, mitochondrial instability, and Ca²⁺ overload.

Authors:  Sylvia Fitting; Pamela E Knapp; Shiping Zou; William D Marks; M Scott Bowers; Hamid I Akbarali; Kurt F Hauser
Journal:  J Neurosci       Date:  2014-09-17       Impact factor: 6.167

Review 8.  Regulation of neuronal ferritin heavy chain, a new player in opiate-induced chemokine dysfunction.

Authors:  Anna Cook Abt; Olimpia Meucci
Journal:  J Neuroimmune Pharmacol       Date:  2011-04-05       Impact factor: 4.147

Review 9.  Opioid and chemokine regulation of cortical synaptodendritic damage in HIV-associated neurocognitive disorders.

Authors:  Bradley Nash; Lindsay Festa; Chihyang Lin; Olimpia Meucci
Journal:  Brain Res       Date:  2019-08-26       Impact factor: 3.252

Review 10.  Functions of the chemokine receptor CXCR4 in the central nervous system and its regulation by μ-opioid receptors.

Authors:  Bradley Nash; Olimpia Meucci
Journal:  Int Rev Neurobiol       Date:  2014       Impact factor: 3.230

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.